Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

Inclusion criteria

• Age 45-85 years;
• International Prostate Symptom Score (IPSS) ≥ 8, indicating moderate to severe Lower Urinary Tract Symptoms (LUTS) that significantly impact quality of life;
• Poor response to pharmacological treatment or refusal of pharmacological treatment;
• Prostate volume 30-80 mL;
• Maximum urinary flow rate (Qmax) < 15 mL/s;
• Post-void residual urine volume (PVR) < 300 mL;
• Willingness to provide informed consent and participate in postoperative follow-up.

Exclusion criteria

• Prostate volume < 30 mL or > 80 mL;
• Severe urinary tract infection;
• Preoperative definitive diagnosis of prostate cancer;
• Known neurogenic bladder, detrusor muscle weakness, urethral stricture, or other non-BPH causes of urinary obstruction;
• Patients with prostatitis;
• History of invasive prostate interventions, such as radiofrequency ablation, laser therapy, or microwave treatment;
• Patients with severe cardiovascular disease, chronic obstructive pulmonary disease, severe diabetes, hepatic or renal dysfunction, or systemic bleeding disorders, as assessed by the investigator to be unsuitable for surgery.